Clinical trials: Treatment Resistant
Type 1 Diabetes Mellitus
TAK-329 Glucose Clamp Study
The purpose of this study is to compare the safety, tolerability, pharmacokinetic and pharmacodynamic properties of single doses of TAK-329 with a single dose of a subcutaneously-injected rapid-acting insulin analog in…
- Trial name
- NCT01311076
- Testing
- TAK-329, Insulin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Takeda
Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Resistant FRα-Positive Fallopian Tube Cancer
Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer
Epithelial ovarian cancer, which includes fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm.
- Conditions
- Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Resistant FRα-Positive Fallopian Tube Cancer, Platinum-Resistant FRα-Positive Peritoneal Cancer
- Trial name
- MIRELA (NCT07896421)
- Where
- Austria
- Volunteers
- 500 people
- Sponsor
- AbbVie
Chronic Myeloid Leukemia
To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib
This study will evaluate the effects of multiple doses of nilotinib on the pharmacokinetics and metabolism of midazolam (as a sensitive CYP3A probe) in CML patients.
- Trial name
- NCT01223898
- Testing
- Tasigna
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension
REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management
The REVEAL Registry™ is a multicenter, observational, U.S.-based study of the clinical course and disease management of pulmonary arterial hypertension (PAH) patients.
- Trial name
- NCT00370214
- Where
- 54 sites in United States
- Volunteers
- 3,515 people
- Sponsor
- Actelion
Community-acquired Pneumonia
Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia
The primary purpose of this study is to effect of Ingaron®, a lyophilisate for the preparation of a solution for intramuscular and subcutaneous administration of 100,000 IU (LLC NPP Farmaklon, Russia) on the effectiveness of…
- Trial name
- NCT05395702
- Testing
- Interferon-Gamma
- Where
- Russia
- Volunteers
- 114 people
- Sponsor
- SPP Pharmaclon Ltd.
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
This a Phase 2a, multicenter, randomized, double-blind, placebo controlled 3 arm study to assess the safety and tolerability of multiple oral doses of REL-1017 25 mg and 50 mg as adjunctive therapy in the treatment of patients…
- Trial name
- NCT03051256
- Testing
- REL-1017
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Relmada Therapeutics, Inc.
Major Depressive Disorder
Treatment-Resistant Depression Registry
This registry will collect information about patients with treatment-resistant depression (TRD) who are currently in a major depressive episode.
- Trial name
- NCT00320372
- Where
- 55 sites in United States
- Volunteers
- 795 people
- Sponsor
- Cyberonics, Inc.
Venous Leg Ulcer
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)
The aim of this clinical trial is to investigate the efficacy and safety of allo-APZ2-CVU, administered topically on therapy-resistant non-healing CVUs compared to placebo.
- Trial name
- NCT06489028
- Testing
- allo-APZ2-CVU
- Where
- 15 sites in United States, Austria and 10 more
- Volunteers
- 250 people
- Sponsor
- RHEACELL GmbH & Co. KG
Ovarian Cancer
A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
This study is an open-label, multicenter Phase Ib/II clinical trial of LBL-024 in combination with other drugs for the treatment of patients with platinum-resistant ovarian cancer (OC), aiming to evaluate the efficacy and safety…
- Trial name
- NCT07042802
- Testing
- LBL-024 for Injection, Paclitaxel injection, Bevacizumab injection
- Where
- 13 sites in China
- Volunteers
- 180 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Castration-Resistant Prostatic Cancer, Metastasis
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT06863272
- Testing
- Docetaxel, Ifinatamab Deruxtecan, Opevesostat
- Where
- 82 sites in United States, Argentina and 17 more
- Volunteers
- 360 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking.
- Trial name
- NCT05701007
- Testing
- abiraterone, enzalutamide, docetaxel
- Where
- Finland
- Volunteers
- 1,083 people
- Sponsor
- Pfizer
Prostate Cancer
Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer
The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.
- Trial name
- NCT00104130
- Testing
- KOS-862
- Where
- 9 sites in United States
- Volunteers
- 53 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate safety and efficacy of Omnitarg (Pertuzumab) on cancerous lesions in men with castration-resistant (hormone-refractory) prostate cancer.
- Trial name
- NCT00058539
- Testing
- rhuMAb 2C4 (pertuzumab)
- Volunteers
- 42 people
- Sponsor
- Genentech, Inc.
High Blood Pressure, Metabolic Syndrome
Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome
The purpose of this study was to determine the effects of Aliskiren on insulin resistance (IR) and endothelial dysfunction (ED) in patients with high blood pressure and metabolic syndrome.
- Conditions
- High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
- Trial name
- NCT00417170
- Testing
- Aliskiren, Amlodipine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
The aim of this study was to assess the characteristics, treatment patterns, and clinical outcomes among metastatic castration-resistant prostate cancer (mCRPC) patients in the United States (US) who were treated with…
- Trial name
- NCT07477756
- Where
- United States
- Volunteers
- 1,247 people
- Sponsor
- Novartis Pharmaceuticals
Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A lead-in cohort of ~20 patients with primary or secondary myelofibrosis previously treated with 1 or more Janus kinase inhibitors enrolled to single-agent glasdegib to evaluate safety and tolerability.
- Trial name
- NCT02226172
- Testing
- Glasdegib (PF-04449913)
- Where
- 19 sites in United States, Japan
- Volunteers
- 21 people
- Sponsor
- Pfizer
Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis
Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis
The purpose of this study is to determine whether nalfurafine hydrochloride is effective and safe in the treatment for conventional-treatment-resistant pruritus in patients receiving hemodialysis.
- Trial name
- TRK-820 (NCT01513161)
- Testing
- nalfurafine hydrochloride (TRK-820)
- Where
- South Korea
- Volunteers
- 104 people
- Sponsor
- SK Chemicals Co., Ltd.
Major Depressive Disorder
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
The purposes of this study are to determine: Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression.
- Trial name
- NCT00035321
- Testing
- Olanzapine, Fluoxetine
- Where
- 33 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Ventilator Associated Pneumonia
PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB
A multicenter Phase 2 study to evaluate the pharmacokinetics, efficacy, and safety of intravenous BV100 combined with Polymyxin B in adult patients with VABP suspected or confirmed to be due to CRAB
- Trial name
- NCT05685615
- Testing
- BV100 plus Polymyxin B, BAT
- Where
- 16 sites in Georgia, Greece and 1 more
- Volunteers
- 39 people
- Sponsor
- BioVersys AG
Vulvovaginal Candidiases, Yeast Infection
Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis
This is a single-center, open-label, pilot study to evaluate the efficacy of 14 days of CAMB dosing in subjects with fluconazole-resistant vulvovaginal candidiasis (VVC).
- Conditions
- Vulvovaginal Candidiases, Yeast Infection, Vulvovaginitis, Yeast Infection Vaginal
- Trial name
- NCT03167957
- Testing
- Oral Encochleated Amphotericin B (CAMB)
- Where
- United States
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.